The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis Off J WASOG World Assoc Sarcoidosis Granulomatous Disord, 18 avr, vol.31, pp.19-27, 2014. ,
Nemesis of neglected neurosarcoidosis, Ann Clin Transl Neurol. oct, vol.2, issue.10, pp.947-955, 2015. ,
CNS inflammation other than multiple sclerosis: How likely is diagnosis?, Neurology. 1 avr, vol.82, issue.13, pp.1187-1196, 2014. ,
Central nervous system sarcoidosisdiagnosis and management, QJM. 1 févr, vol.92, issue.2, pp.103-120, 1999. ,
, Sarcoidosis. The Lancet. mars, vol.383, issue.9923, pp.1155-67, 2014.
Genetics of Sarcoidosis, Proc Am Thorac Soc. janv, vol.4, issue.1, pp.108-124, 2007. ,
, Sarcoidosis | NEJM
Kunt Uzaslan E. ACE gene I/D polymorphism and risk of sarcoidosis development in Turkish patients, Tuberk Ve Toraks. 21 sept, pp.201-207, 2012. ,
Meta-analytical association between angiotensin-converting enzyme gene polymorphisms and sarcoidosis risk, Genet Mol Res, vol.14, issue.2, pp.3590-600, 2015. ,
Vitamin D Receptor Gene Polymorphism in Patients with Sarcoidosis, Am J Respir Crit Care Med, vol.160, issue.4, pp.1107-1116, 1999. ,
A Case Control Etiologic Study of Sarcoidosis: Environmental and Occupational Risk Factors, Am J Respir Crit Care Med. 15 déc, vol.170, issue.12, pp.1324-1354, 2004. ,
, Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. Chest. janv, vol.153, issue.1, pp.114-137, 2018.
Paris VII; 2009. 14. Dubaniewicz A. Microbial and human heat shock proteins as 'danger signals' in sarcoidosis, Caractéristiques cliniques, biologiques, radiologiques et profils évolutif des neurosarcoïdoses : études rétrospectives de 197 patients, vol.74, pp.1550-1558, 2013. ,
Cellular Activation in the Immune Response of Sarcoidosis, Semin Respir Crit Care Med. 9 juill, vol.35, issue.03, pp.307-322, 2014. ,
Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group, JAMA Neurol. 1 déc, vol.75, issue.12, pp.1546-53, 2018. ,
Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis, J Neurooncol. janv, vol.91, issue.1, pp.113-119, 2009. ,
Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images, Am J Roentgenol. déc, vol.155, issue.6, pp.1293-301, 1990. ,
Virchow-Robin space: a path of spread in neurosarcoidosis, Radiology. mars, vol.158, issue.3, pp.715-735, 1986. ,
,
, Cranial Base Manifestations of Neurosarcoidosis: A Review of 305 Patients, Otol Neurotol. juill, vol.1, 2014.
Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan, Pathol Int. juill, vol.43, issue.7-8, pp.372-378, 1993. ,
MR of CNS Sarcoidosis: Correlation of Imaging Features to Clinical Symptoms and Response to Treatment. 1999;15. 23. Statement on sarcoidosis ,
, ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, 24. Scadding JG. Prognosis of Intrathoracic Sarcoidosis in England, vol.160, pp.1165-72, 1961.
Validation of international criteria for the diagnosis of ocular sarcoidosis proposed by the first international workshop on ocular sarcoidosis, Jpn J Ophthalmol, vol.54, issue.6, pp.529-565, 2010. ,
Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis, Heart. 1 mars, vol.102, issue.6, pp.411-415, 2016. ,
Neurosarcoidosis: signs, course and treatment in 35 confirmed cases, Medicine (Baltimore). sept, vol.69, issue.5, pp.261-76, 1990. ,
Neurosarcoidosis: A Personal Perspective Based on the Study of 37 ,
, Patients. CHEST. 1 juill, vol.112, issue.1, pp.220-228, 1997.
Les atteintes neurologiques au cours de la sarcoïdose : diagnostic et traitement. Rev Médecine Interne, vol.38, pp.393-401, 2017. ,
Sarcoïdose du système nerveux central: polymorphisme clinique et radiologique, Rev Médecine Interne. 1 juin, vol.17, issue.6, pp.482-489, 1996. ,
,
, Sarcoidosis Centers. The Neurologist, vol.18, pp.373-380, 2012.
Optic neuropathy associated with systemic sarcoidosis. Neurol Neuroimmunol Neuroinflammation, vol.3, p.270, 2016. ,
Maladie veineuse thromboembolique dans une cohorte de 770 cas de sarcoïdoses, Rev Médecine Interne. déc, vol.38, p.42, 2017. ,
G -22 Lésions vasculaires cérébrales et sarcoïdose, Rev Neurol (Paris). 1 avr, vol.163, issue.4, p.28, 2007. ,
Isolated Central Nervous System Vasculitis as a Manifestation of Neurosarcoidosis, J Stroke Cerebrovasc Dis. juin, vol.341, issue.1-2, pp.89-92, 2014. ,
Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study, Medicine (Baltimore). mars, vol.89, issue.2, pp.133-173, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00795763
The natural history and long-term outcome of 57 limb sarcoidosis neuropathy cases, J Neurol Sci. mai, vol.244, issue.1-2, pp.77-87, 2006. ,
Neurosarcoidosis presenting as an anterior horn syndrome, J Neuroimmunol. 25 août, vol.225, issue.1-2, pp.132-138, 2010. ,
Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: A prospective follow-up study, Respir Med. mai, vol.138, pp.24-30, 2018. ,
Diagnostic strategy for major neurocognitive disorders in the young subject, Prat Neurol -FMC, issue.10, pp.84-95, 2019. ,
Everyday Cognitive Failure in Sarcoidosis: The Prevalence and the Effect of Anti-TNF-? Treatment, Respiration, vol.80, issue.3, pp.212-221, 2010. ,
Neurosarcoidosis: Correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity, J Neurol Sci. déc, vol.335, issue.1-2, pp.124-154, 2013. ,
,
, Genotype-corrected reference values for serum angiotensin-converting enzyme, Eur Respir J. 1 déc, vol.28, issue.6, pp.1085-91, 2006.
Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system, J Neurol Neurosurg Psychiatry. 1 mai, vol.58, issue.5, pp.548-54, 1995. ,
Biomarqueurs du liquide cérébro-rachidien au cours des neurosarcoïdoses : apports diagnostiques et pronostiques, Rev Neurol (Paris). 1 avr, vol.174, p.144, 2018. ,
The cerebrospinal fluid CD4/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study, Eur J Neurol, 2019. ,
Disponible sur, Curr Treat Options Neurol. 1 août, vol.15, issue.4, pp.492-504, 2013. ,
Les manifestations neurologiques de la sarcoïdose : étude de 18 cas, Rev Neurol, vol.171, issue.11, pp.773-81, 2015. ,
Hickam's Dictum, West J Emerg Med. 1 mars, vol.14, issue.2, pp.164-164, 2013. ,
Clinical description of 7 cases with a proposal for a new diagnostic strategy, J Neurol. avr, vol.253, issue.4, pp.488-95, 2006. ,
Neurologic manifestations of sarcoidosis, Handbook of Clinical Neurology, pp.305-338, 2014. ,
Overview of neurosarcoidosis: recent advances, J Neurol. 1 févr, vol.262, issue.2, pp.258-67, 2015. ,
,
, Long-term outcomes of refractory neurosarcoidosis treated with infliximab, J Neurol. mai, vol.264, issue.5, pp.891-898, 2017.
Neurosarcoidosis: a clinical approach to diagnosis and management, J Neurol. mai, vol.264, issue.5, pp.1023-1031, 2017. ,
Treatment of neurosarcoidosis: A comparative study of methotrexate and mycophenolate mofetil, Neurology. 13 déc, vol.87, issue.24, pp.2517-2538, 2016. ,
, Caractéristiques cliniques, biologiques, radiologiques et profil évolutif des neurosarcoïdoses: étude rétrospective de 197 patients, 2009.
Interobserver agreement for the assessment of handicap in stroke patients, Stroke. mai, vol.19, issue.5, pp.604-611, 1988. ,
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology. nov, vol.33, issue.11, pp.1444-52, 1983. ,
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial, Eur Respir J. 5 mars, vol.31, issue.6, pp.1189-96, 2008. ,
Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force, Eur J Neurol, vol.13, issue.9, pp.913-935, 2006. ,
Sarcoidosis and Its Neurological Manifestations, Arch Neurol. 1 sept, vol.42, issue.9, pp.909-926, 1985. ,
, Eur J Intern Med. déc, vol.22, issue.6, pp.125-157, 2011.
,
, Neurosarcoidosis according to Zajicek and Scolding criteria: 15 probable and definite cases, their treatment and outcomes, J Neurol Sci. août, vol.379, pp.84-92, 2017.
Presentations and outcomes of neurosarcoidosis: a study of 54 cases, QJM Int J Med. juill, vol.102, issue.7, pp.449-60, 2009. ,
Neurosarcoidosis: clinical presentations and course in 50 patients, Acta Neurol Scand. 1 mars, vol.73, issue.3, pp.283-90, 1986. ,
Long-term follow-up of neurosarcoidosis, Neurology. 11 sept, vol.57, issue.5, pp.927-936, 2001. ,
Central Nervous System Sarcoidosis: Follow-up at MR Imaging during Steroid Therapy, Radiology. 1 févr, vol.214, issue.2, pp.411-431, 2000. ,
Neurosarcoidosis: a study of 30 new cases, J Neurol Neurosurg Psychiatry. 1 mars, vol.80, issue.3, pp.297-304, 2009. ,
Clinical and magnetic resonance imaging manifestations of neurosarcoidosis, Semin Arthritis Rheum. 1 févr, vol.34, issue.4, pp.649-61, 2005. ,
Aggressive Therapy for Neurosarcoidosis: Long-term Follow-up of 48 Treated Patients, Arch Neurol. 1 mai, vol.64, issue.5, pp.691-697, 2007. ,
Discrimination of spinal cord sarcoidosis from neuromyelitis optica spectrum disorer or spondylotic myelopathy, J Neurol Sci, vol.381, pp.449-50, 2017. ,
Teaching NeuroImages: Diffuse cerebral neurosarcoidosis mimicking gliomatosis cerebri, Am Acad Neurol, issue.e46, 2013. ,
SarcoidosisThe Greatest Mimic, Semin Ultrasound CT MRI. juin, vol.35, issue.3, pp.215-239, 2014. ,
Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis, BMC Neurol [Internet]. déc, vol.16, issue.1, pp.1864-1872, 1997. ,
, Johns Carol J. Neurosarcoidosis. Ann N Y Acad Sci. juin, vol.465, issue.1, pp.722-752, 1986.
Neurosarcoïdose : état des connaissances, Rev Neurol, vol.162, issue.12, pp.1173-88, 2006. ,
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis, The Lancet. déc, vol.364, issue.9451, pp.2106-2118, 2004. ,
Myelinoligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype, Neurology, vol.79, issue.12, pp.1273-1280, 2012. ,
Disponible sur, vol.13, 2016. ,
Neurosarcoidosis presenting as major depression, J Neurol Neurosurg Psychiatry. 1 sept, vol.47, issue.9, pp.1050-1051, 1984. ,
,
, Rev Neurol (Paris), vol.156, pp.965-75, 2000.
Multiple Sclerosis and Sarcoidosis : A case for co-existence, 2018. ,
Peripheral Blood of Sarcoidosis Patients Correlates with Severe Disease Manifestations, Zimmer J, éditeur. PLoS ONE. 5 févr, vol.5, issue.2, p.9088, 2010. ,
The immune paradox of sarcoidosis and regulatory T cells, J Exp Med. 20 févr, vol.203, issue.2, pp.359-70, 2006. ,
The Prevalence of ,
A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century, Antinuclear Antibodies in Patients with Sarcoidosis. Autoimmune Dis, vol.16, pp.472-481, 2010. ,
The role of 18F-FDG-PET and PET/CT in Patients with Sarcoidosis : an update Evidence-based review, Acad Radiol. mai, vol.21, issue.5, pp.675-84, 2014. ,
MRI and PET imaging discordance in neurosarcoidosis, vol.79, pp.1070-1070, 2012. ,
Functional imaging in extrapulmonary sarcoidosis : FDG-PET/CT and MRI features, Clin Nucl Med, vol.39, issue.2, pp.146-59, 2014. ,
18F-FDG PET/CT for the Assessment of Disease Extension and Activity in Patients With Sarcoidosis: Results of a Preliminary Prospective Study, Clin Nucl Med. avr, vol.38, issue.4, pp.171-178, 2013. ,
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis, J Neurol Sci. 15 déc, vol.287, issue.1, pp.257-266, 2009. ,
Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis, J Nucl Med, vol.47, issue.10, pp.1571-1577, 2006. ,
Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung, Clin Exp Immunol, vol.108, pp.105-118, 1997. ,
Dynamics and Mechanism of the Sarcoidal Granuloma Detecting T Cell Subsets, Non-T Cells, and Immunoglobulins in Biopsies at Varying Intervals of Kveim-Siltzbach Test Sites, Ann N Y Acanemy Sci, issue.465, pp.221-253, 1986. ,
Interstitial lung disease: the diagnostic role of bronchoscopy, J Thorac Dis. sept, vol.9, issue.10, pp.996-1010, 2017. ,
Role of Pulmonary Evaluation in Diagnosis of Neurosarcoidosis | Sarcoidosis vasculitis and diffuse lung disease, 2016. ,
Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET. Semin Respir Crit Care Med, août, vol.31, issue.04, pp.404-412, 2010. ,
Causes et caractéristiques des décès en réanimation : une étude nationale, Anesth Réanimation. sept, vol.1, pp.375-381, 2015. ,
Mortalité intrahospitalière après une prise en charge en réanimation médicale : identification des facteurs prédictifs. Université d'Anger, 2014. ,
,
NS) is a rare and polymorphic entity, often inaugural and isolated. To date, diagnostic assessment is still a matter of debate ,
, A retrospective study of all patients diagnosed with NS was conducted in Rouen University Hospital between 1992 and 2018. We included patients diagnosed with definite, probable and possible NS, as described by the Neurosarcoidosis Consortium Group 2018 and collected clinical, biological and imaging data
, Possible NS were up-represented about 6% compared to previous Marangoni et al criteria. The median time to diagnostic was 3.0 months. In cases of already known sarcoidosis, neurological symptoms mainly occurred within 6 months after the onset of sarcoidosis (54%), A total of 35 patients were included, 24 (69%) of whom with inaugural NS. Sex ratio male/female was 0.84
, No difference was found in terms of demographic features, biological tests and imaging in subgroup between: inaugural NS or not, age, sex. Women younger than 40 years seemed to have more cranial nerve palsy and a better prognosis
MRI, EMG) abnormal was 94.3% showing the interest of these three investigations in suspected cases of NS XII. COMMUNICATIONS AFFICHEES Neurosarcoidosis : report of 30 cases. What about diagnosis dilemma ?, Here we highlight application of 2018 diagnosis consensus criteria of NS. Probability having at least one of the following (CSF ,
ECTRIMS 2019. 10/10/2019. RESUME INTRODUCTION : La sarcoïdose est une granulomatose systémique caractérisée par de granulomes épithélioïdes et gigantocellulaires sans nécrose caséeuse. La neurosarcoïdose est une présentation rare (5%), polymorphe, souvent révélatrice (75%), parfois isolée (15%), New consensus diagnosis criteria of Neurosarcoidosis: Application in a French, 2018. ,
Il s'agit de l'étude rétrospective d'une cohorte de patients présentant une atteinte neurologique de sarcoïdose monocentrique au CHU de Rouen de 1992 à 2018. Tout patient remplissant les critères diagnostic selon Stern ,
, Les atteintes du système nerveux central étaient prédominantes : céphalées (49%), atteinte des NC (57%), parenchymateuse (29%) (dont les crises convulsives), puis médullaire (17%) ou périphérique (11%). La probabilité d'avoir au moins une anomalie parmi LCR, IRM cérébrale et/ou médullaire et ENMG était de 94,3%. Le LCR retrouvait typiquement une méningite lymphocytaire (86%) et une hyperproteinorrachie chez (71%). L'IRM révélait des lésions inflammatoires focales (73%) et diffuses (87%). Les examens biologiques montraient : une lymphopénie (71%), RESULTATS : 35 patients ont été inclus dont 24 (69%) NS inaugurale. Le sexe ratio H/F était 0,84. L'âge médian de début était 48,0 ans. La neurosarcoïdose était définie 4 (11%), probable 17 (49%) ou possible 14 (40%)
, CONCLUSION : La neurosarcoïdose est caractérisée par son polymorphisme clinique et paraclinique. En cas de suspicion de maladie inflammatoire du système nerveux central, certains signes évocateurs sont : notamment la présence de céphalées, d'une atteinte des NC, de manifestations extra neurologiques. La prévalence des anomalies aux examens de première intention LCR, IRM, ENMG et l'importante dissociation avec la clinique incitent à une
, MOTS CLES : Neurosarcoïdose, définie, probable, possible, phénotype, rentabilité